Alexandre Brind'Amour

Dr. Alexandre Brind'Amour

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2021 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
ABAlexandre Brind'Amour
Alexandre Brind'Amour
MWMitchell Webb
Mitchell Webb
MPMarina Parapini
Marina Parapini
LSLucas Sidéris
Lucas Sidéris
MSMaja Segedi
Maja Segedi
PKPeter T. W. Kim
Peter T. W. Kim

28 August 2022 in HPB
Verified
Journal Article
Closed access
TLTori Lenet
Tori Lenet
RGRichard W.D. Gilbert
Richard W.D. Gilbert
JAJad Abou-Khalil
Jad Abou-Khalil
FBFady K. Balaa
Fady K. Balaa
GMGuillaume Martel
Guillaume Martel
KBKimberly A. Bertens
Kimberly A. Bertens

1 September 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ABAlexandre Brind'Amour
Alexandre Brind'Amour
VPVera Pravong
Vera Pravong
Lucas SiderisLucas Sideris
Lucas Sideris
PDPierre Dubé
Pierre Dubé
LGLara De Guerke
Lara De Guerke
JTJean-François Tremblay
Jean-François Tremblay

29 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MKMaher Al Khaldi
Maher Al Khaldi
MFMassine Fellouah
Massine Fellouah
PDPierre Drolet
Pierre Drolet
JCJulien Côté
Julien Côté
BTBertrand Trilling
Bertrand Trilling
Lucas SiderisLucas Sideris
Lucas Sideris
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a treatment option for peritoneal metastases (PM) but is associated with significant postoperative morbidity. The aim of this study was to determine the prognostic value of computed tomographic (CT)-measured sarcopenia on postoperative outcomes and survival in patients undergoing CRS-HIPEC for PM from various origins. A retrospective cohort study was conducted between 2012 and 2020. Three-hundred and twelve patients (mean age 57.6 ± 10.3, 34.3% male) were included, of which 88 (28.2%) were sarcopenic. PM from a colorectal origin was the most common in both groups. The proportion of major postoperative complications (Clavien-Dindo ≥ III) was not higher in the sarcopenic group (15.9% in sarcopenic patients vs. 23.2% in nonsarcopenic patients, p = 0.17). The mean Comprehensive Complication Index scores, HIPEC-related toxicities, length of hospital stay, and duration of parenteral nutrition were comparable regardless of sarcopenia status. In the multivariate logistic regression analysis of severe complications, only peritoneal carcinomatosis index reached statistical significance (OR, 1.05; 95% CI, 1.01 to 1.08, p = 0.007). Sarcopenia did not impact origin-specific overall survival on Cox regression analysis. Sarcopenia was not associated with worse rates of postoperative severe complications or worse survival rates. Future prospective studies are required before considering sarcopenia as part of preoperative risk assessment.

20 May 2025 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
JCJanyssa Charbonneau
Janyssa Charbonneau
PNPatricia Noël
Patricia Noël
JOJean-François Berthin Ouellet
Jean-François Berthin Ouellet
IDIsabelle Deshaies
Isabelle Deshaies
CDCarl Daigle
Carl Daigle
ABAlexandre Brind'Amour
Alexandre Brind'Amour

1 December 2020 in Current Oncology
Verified
Journal Article
Open access
PDF file
FSFarhana Shariff
Farhana Shariff
DBDanielle Bischof
Danielle Bischof
AGAnand Govindarajan
Anand Govindarajan
RPRebecca Prince
Rebecca Prince
RBRonald Burkes
Ronald Burkes
AMAndrea McCart
Andrea McCart
Background: The COVID-19 pandemic has put enormous pressure on hospital resources, and has affected all aspects of patient care. As operative volumes decrease, cancer surgeries must be triaged and prioritized with careful thought and attention to ensure maximal benefit for the maximum number of patients. Peritoneal malignancies present a unique challenge, as surgical management can be resource intensive, but patients have limited non-surgical treatment options. This review summarizes current data on outcomes and resource utilization to help inform decision-making and case prioritization in times of constrained health care resources. Methods: A rapid literature review was performed, examining surgical and non-surgical outcomes data for peritoneal malignancies. Narrative data synthesis was cross-referenced with relevant societal guidelines. Peritoneal malignancy surgeons and medical oncologists reviewed recommendations to establish a national perspective on case triage and mitigating treatment strategies. Results and Conclusions: Triage of peritoneal malignancies during this time of restricted health care resource is nuanced and requires multidisciplinary discussion with consideration of individual patient factors. Prioritization should be given to patients where delay may compromise resectability of disease, and where alternative treatment options are lacking. Mitigating strategies such as systemic chemotherapy and/or surgical deferral may be utilized with close surveillance for disease stability or progression, which may affect surgical urgency. Unique hospital capacity, and ability to manage the complex post-operative course for these patients must also be considered to ensure patient and system needs are aligned.